The pharmaceutical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s exhibiting significant promise in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a more substantial decrease in body mass and benefit metabolic function,